|
1. Biologie
|
|
|
|
|
3.1 Tabac
|
|
|
|
How to “nudge” smokers to reduce tobacco use? [Now@NEJM]
|
|
|
|
|
|
In
a NEJM Perspective, Fiore and Baker from the Center for Tobacco
Research and Intervention at the University of Wisconsin School of
Medicine believe “these data support exploration of a national
nicotine-reduction policy, and we recommend that additional attention be
paid to low-nicotine cigarettes as a potential clinical
smoking-cessation resource”.
|
|
|
|
|
|
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
Progress in mainstreaming genomics into clinical practice [PHG Foundation]
|
|
|
|
|
|
For
all areas of clinical practice, the education of health professionals
is key to patients being able to access high quality genomic services.
The ASCO policy update highlights the need for professionals to develop
core competences in genetics - a level of knowledge that typically
exceeds that received during training.
|
|
|
|
|
5. Traitements
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
5.4 Traitements - Economie
|
|
|
UK launch for Roche's Perjeta in early breast cancer [NICE]
|
|
|
|
|
|
Perjeta
was deemed too expensive by the National Institute for Health and Care
Excellence for routine NHS use, but is still available to patients with
previously-untreated advanced disease through England’s Cancer Drugs
Fund, although it isn’t currently listed on the CDF in the early
indication.
|
|
|
|
|
|
|
|
Drug Price Demagoguery Could Hurt Patients [Forbes]
|
|
|
|
|
|
We
need a real conversation about “pay for performance,” where drugs that
can prove their worth are reimbursed more. We also need real recognition
that is it fine to reward innovators generously for creating drugs that
cure people and save money. We should make no apologies for a $100,000
drug that can prove it saves society money and treats Alzheimer’s.
|
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
|
6.4 Médico-éco
|
|
|
What is the cost of lung cancer in Germany? [AlphaGalileo]
|
|
|
|
|
|
Average
financial expenditure per case of lung cancer amounted to about 20.000
euros. However, this amount varied immensely, depending on the type of
treatment provided. The striking feature was that one fifth of patients
did not receive targeted cancer therapy.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
|
6.8 Communication
|
|
|
|
6.9 Controverses
|
|
|